The Remote Opioid Monitoring Act of 2025 would direct the Comptroller General, through the Government Accountability Office, to study the use of remote monitoring for individuals prescribed opioids. The study would be due within 18 months of enactment and would be submitted to the House Committee on Energy and Commerce and to the Senate committees with jurisdiction over health and finance matters.
The required report would evaluate scientific evidence on whether remote monitoring improves outcomes, reduces harms, or saves money compared with no monitoring. It would also examine how common remote monitoring is in the United States and abroad, and recommend ways to improve availability, access, and coverage, including possible changes to federal health care programs. If appropriate, the Comptroller General could also identify patient groups most likely to benefit from remote monitoring when prescribed opioids.
Impact
This bill does not itself change substantive federal law or create a new program; instead, it requires a federal study and recommendations that could inform later legislation, regulation, or coverage decisions. Its practical effect would be to place opioid-related remote monitoring under formal federal review, potentially influencing Medicare, Medicaid, and other federal health care program policies if the study finds evidence supporting broader use.
Sentiment
The bill appears to have a generally supportive, exploratory tone, with sponsors seeking evidence on a potentially useful tool in opioid care rather than mandating immediate policy changes. Because there are no recorded committee transcripts or votes in the provided material, there is no documented opposition or floor-level debate to indicate broader controversy. The measure’s framing suggests interest in improving patient safety, access, and cost-effectiveness through data-driven evaluation.
Contention
The main potential points of contention are likely to be the strength of the evidence for remote monitoring, privacy and implementation concerns, and whether federal health programs should expand coverage before more definitive results are available. Stakeholders who may favor the bill include opioid treatment advocates, clinicians, and policymakers focused on overdose prevention and care coordination. Those who may be cautious include privacy advocates, payers, and others concerned about costs, surveillance burdens, or uncertain clinical benefit.
Allows remote patient monitoring of pregnant patients; requires reimbursement for remote patient monitoring rendered to certain Medicaid beneficiaries.